Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Net Income/ Starting Line | 1.01 | 0.98 | -0.95 | 0.35 |
Depreciation/ Depletion | 1.20 | 0.81 | 1.09 | 1.27 |
Non- Cash Items | 0.33 | 0.29 | 0.29 | -0.13 |
Changesin Working Capital | -1.72 | 0.39 | -0.72 | -1.11 |
Cashfrom Operating Activities | 0.82 | 2.48 | -0.29 | 0.38 |
Capital Expenditures | -1.35 | -1.56 | -0.42 | -1.05 |
Other Investing Cash Flow Items Total | 0.27 | 0.26 | 0.95 | 1.31 |
Cashfrom Investing Activities | -1.08 | -1.30 | 0.54 | 0.26 |
Financing Cash Flow Items | -0.45 | -0.42 | -0.43 | -0.47 |
Issuance( Retirement)of Debt Net | 0.55 | -0.75 | 0.00 | -0.11 |
Cashfrom Financing Activities | 0.10 | -1.17 | -0.43 | -0.58 |
Net Changein Cash | -0.16 | 0.01 | -0.18 | 0.06 |
Cash Interest Paid | 0.46 | 0.42 | 0.43 | 0.47 |
Cash Taxes Paid | 0.20 | 0.06 | 0.10 | 0.02 |
Beryl Drugs Dividend Beryl Drugs Bonus Beryl Drugs News Beryl Drugs AGM Beryl Drugs Rights Beryl Drugs Splits Beryl Drugs Board Meetings Beryl Drugs Key Metrics Beryl Drugs Shareholdings Beryl Drugs Profit Loss Beryl Drugs Balance Sheet Beryl Drugs Q1 Results Beryl Drugs Q2 Results Beryl Drugs Q3 Results Beryl Drugs Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks